HENDERSON JOHN T 4

What Happened

• John T. Henderson, a director of Cytokinetics, was granted and acquired 272 shares of CYTK common stock on 2026-07-15 at a reported value of $82.62 per share, for a total value of $22,473. The grant is reported as an award/acquisition (transaction code A) and the shares are fully vested at the time of grant.

Key Details

• Transaction date: 2026-07-15; Form 4 filed: 2026-07-16 (filed promptly).
• Price/value: $82.62 per share; total value $22,473.
• Shares acquired: 272 shares.
• Vesting/notes: Footnote F1 — shares granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program and are fully vested at grant.
• Shares owned after transaction: not specified in the provided filing.
• No tax-withholding or 10b5-1 plan noted in this filing.

Context

• This was a compensation-related award (equity received instead of a cash retainer), which is common for board members and reflects compensation rather than an open-market purchase or sale. Such awards are routine and do not by themselves indicate the director’s view of the company’s prospects.